Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

被引：0
|
作者：
Gyorffy, Balazs
Santarpia, Libero
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-03-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-03-07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters
    Stanowska, Olga
    Kuczkiewicz-Siemion, Olga
    Debowska, Malgorzata
    Olszewski, Wojciech P.
    Jagiello-Gruszfeld, Agnieszka
    Tysarowski, Andrzej
    Prochorec-Sobieszek, Monika
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [32] Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative
    Vidula, Neelima
    Ellisen, Leif W.
    Bardia, Aditya
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (01): : 109 - 117
  • [33] Antibody Drug Conjugates for Triple-Negative Breast Cancer: Targeting Positive in the Negative
    Bardia, Aditya
    ONCOLOGIST, 2017, 22 : S3 - S3
  • [34] Prognostic significance of PD-L1 expression on cancer, stromal, or immune cells in triple-negative breast cancer
    Behrendt, Carolyn E.
    Schmolze, Daniel B.
    Lee, Peter P.
    Apple, Sophia
    LABORATORY INVESTIGATION, 2018, 98 : 50 - 50
  • [35] Prognostic significance of PD-L1 expression on cancer, stromal, or immune cells in triple-negative breast cancer
    Behrendt, Carolyn E.
    Schmolze, Daniel B.
    Lee, Peter P.
    Apple, Sophia
    MODERN PATHOLOGY, 2018, 31 : 50 - 50
  • [36] Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    Alessandra Fabi
    Luisa Carbognin
    Andrea Botticelli
    Ida Paris
    Paola Fuso
    Maria Cristina Savastano
    Nicla La Verde
    Carla Strina
    Rebecca Pedersini
    Stefania Guarino
    Giuseppe Curigliano
    Carmen Criscitiello
    Mimma Raffaele
    Alessandra Beano
    Antonio Franco
    Maria Rosaria Valerio
    Francesco Verderame
    Andrea Fontana
    Eva Regina Haspinger
    Alessia Caldara
    Alba Di Leone
    Giampaolo Tortora
    Diana Giannarelli
    Giovanni Scambia
    npj Breast Cancer, 10
  • [37] Association PD-L1 overexpression with immune checkpoint inhibitor effect in triple-negative breast cancer
    Park, A. Young
    Kim, Ju Hee
    Lee, Sangen
    Kim, Hong Kyu
    Lee, Han-Byoel
    Han, Wonshick
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    Alessandra Fabi
    Luisa Carbognin
    Andrea Botticelli
    Ida Paris
    Paolo Fuso
    Maria Cristina Savastano
    Nicla La Verde
    Carla Strina
    Rebecca Pedersini
    Stefania Guarino
    Giuseppe Curigliano
    Carmen Criscitiello
    Mimma Raffaele
    Alessandra Beano
    Antonio Franco
    Maria Rosaria Valerio
    Francesco Verderame
    Andrea Fontana
    Eva Regina Haspinger
    Alessia Caldara
    Alba Di Leone
    Giampaolo Tortora
    Diana Giannarelli
    Giovanni Scambia
    npj Breast Cancer, 9
  • [39] MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
    Maeda, Takahiro
    Hiraki, Masayuki
    Jin, Caining
    Rajabi, Hasan
    Tagde, Ashujit
    Alam, Maroof
    Bouillez, Audrey
    Hu, Xiufeng
    Suzuki, Yozo
    Miyo, Masaaki
    Hata, Tsuyoshi
    Hinohara, Kunihiko
    Kufe, Donald
    CANCER RESEARCH, 2018, 78 (01) : 205 - 215
  • [40] Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
    Brumec, Masa
    Sobocan, Monika
    Takac, Iztok
    Arko, Darja
    CANCERS, 2021, 13 (07)
12345